Investor Village needs your help. We are working hard to improve your user experience by upgrading the site so it works better on the latest mobile devices, browsers, O/S, etc.Because costs exceed our normal operating budget, we are asking everyone, including "lurkers," to support our efforts.
Mayo Clinic purchases approximately $1M of BioSig Technologies stock
In a regulatory filing, BioSig Technologies disclosed that on July 5, the Mayo Foundation for Medical Education and Research exercised its warrant to purchase 252,000 shares of common stock of BioSig Technologies at an exercise price of $3.75 per share. The Warrant was issued to Mayo Clinic pursuant to a know-how license agreement entered into between the company and Mayo Clinic dated March 15, 2017. The Warrant had an expiration date of March 15, 2020. The company received an aggregate exercise price of $945,000 from Mayo Clinic. :theflyonthewall.com
BioSig Technologies announced that it has been added as a member of the broad-market Russell 3000 Index, effective after the U.S. market opens on July 1, as part of the 2019 Russell US Indexes reconstitution. :theflyonthewall.com
BioSig Technologies issues June 2019 shareholder letter
BioSig Technologies announced that the Company has issued their June 2019 Shareholder Letter, highlighting patient cases using PURE EP System at three different medical centers, strengthening of patent portfolio and publication strategy, inclusion on the Russell 3000 Index, and other milestones moving toward commercialization. "The highlight of first five months of 2019 was, of course, the success of our first patient cases using PURE EP System at three different medical institutions," stated Mr. Kenneth Londoner, Founder, Chairman and CEO of BioSig Technologies. "BioSig attended the Heart Rhythm Society's 40th Annual Scientific Sessions and received outstanding feedback and support from the medical and scientific community. We have been working diligently towards commercialization and are excited that the PURE EP System has delivered great results during the first phase of external evaluation. Every area of our business has been solidified in the first five months of 2019 - strong balance sheet, exceptional human talent, first class clinical partners and robust intellectual property portfolio all mean that we've never been stronger as a Company. We would like to thank all our loyal shareholders - we never take your support for granted and will continue to work tirelessly on your behalf." :theflyonthewall.com
Please add the Syndicate Deals subscription to see this data.
There are no Conference Calls for these search parameters.
There are no Syndicate Roadshows for these search parameters.
There are no Conferences for these search parameters.
There are no Company Events for these search parameters.
There are no Analyst Events for these search parameters.
There are no Government Events for these search parameters.